Skip to main content

Table 1 Number of samples analyzed for each tumor type and stage

From: The prognostic potential of alternative transcript isoforms across human tumors

   T N M S
Tumor type Acronym Early Late Early Late Early Late Early Late
Breast invasive carcinoma BRCA 256 (T1) 147 (T3, T4) 455 (N0) 171 (N2, N3) 836 (M0) 15 (M1) 164 (S1) 15 (S4)
Colon adenocarcinoma COAD 45 (T1, T2) 31 (T4) 149 (N0) 39 (N2) 179 (M0) 33 (M1) 40 (S1) 34 (S4)
Head and neck squamous cell carcinoma HNSC 35 (T1) 110 (T4) 166 (N0) 166 (N2, N3)    77 (S1, S2) 169 (S4)
Kidney chromophobe KICH 20 (T1) 19 (T3, T4)      20 (S1) 19 (S3, S4)
Kidney renal clear cell carcinoma KIRC 245 (T1) 186 (T3, T4) 233 (N0) 16 (N1) 419 (M0) 77 (M1) 240 (S1) 78 (S4)
Kidney renal papillary carcinoma KIRP 71 (T1) 38 (T3, T4) 23 (N0) 16 (N1, N2)    66 (S1) 38 (S3, S4)
Lung squamous cell carcinoma LUSC 93 (T1) 59 (T3, T4) 242 (N0) 37 (N2, N3)    195 (S1) 76 (S3, S4)
Lung adenocarcinoma LUAD 137 (T1) 57 (T3, T4) 281 (N0) 70 (N2, N3) 307 (M0) 22 (M1) 99 (S1) 242 (S3, S4)
Ovarian serous cystadenocarcinoma OV        18 (S2) 243 (S4)
Prostate adenocarcinoma PRAD 69 (T2) 93 (T3, T4) 129 (N0) 14 (N1)     
Skin cutaneous melanoma SKCM      68 (M0) 17 (M1)   
Thyroid carcinoma THCA 137 (T1) 179 (T3, T4) 220 (N0) 211 (N1)    270 (S1) 48 (S4)
  1. The number of samples used for the comparison early versus late are indicated for each annotation T, N, M, S. Stages I, II, III, and IV are indicated as S1, S2, S3, and S4, respectively. Comparisons were performed between the earliest and latest available stage groups, with some exceptions for which adjacent stages were added to have enough samples for comparison. Empty cells correspond to cases not tested due to lack of sufficient samples or complete lack of annotation in the samples